secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001125345-24-000149
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q2 net loss $55.7M; receives $100M Incyte milestone
---------------------------------------------------------------

- Net loss of $55.7M ($0.89 diluted EPS) vs net income of $57.5M in Q2 2023.
- Revenue of $10.8M, down from $13.1M YoY, driven by lower Provention revenue.
- Cash $140.4M at June 30; $100M Incyte milestone received post-quarter extends cash runway into 2026.
- TAMARACK Phase 2 mCRPC data (vobra duo) to be presented at ESMO in September 2024.
- MGC028 IND expected by end 2024; LORIKEET Phase 2 enrollment completion anticipated in 2024/early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/0001125345-24-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/mgnx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer